Dr. Reedy welcomes Dr. Alexa Altman where she discusses how psychedelics bring the unconscious material into consciousness. She talks about the importance of integration. Dr. Altman’s Website: https://www.i-psychedelic.com 1. Single-dose psilocybin (25 mg) with psychological support for MDDJAMA – “Single-Dose Psilocybin Treatment for Major Depressive Disorder” psychiatryonline.org+15sunstonetherapies.com+15pmc.ncbi.nlm.nih.gov+15 Summary: Demonstrated strong antidepressant effects and good tolerability over follow-up. Email: info@hopkinspsychedelic.org 2. One-Year Follow-Up of Psilocybin for DepressionStudy: Long-term effects of psilocybin therapy for depressionJohns Hopkins – “Psilocybin treatment for major depression effective for up to a year” Summary: 67% of participants remained in remission one year post-treatment.3. MDMA-Assisted Therapy for Severe PTSDRandomized, placebo-controlled MDMA-assisted therapyNature Medicine – “MDMA-assisted therapy for severe PTSD” Summary: Significant reduction in PTSD symptoms, well‑tolerated in a diverse cohort.Contact (MAPS / Lykos Therapeutics): Email: info@maps.org 4. Psilocybin for Cancer-Related Anxiety & DepressionPsilocybin in patients with life-threatening cancerPMC – “High-dose psilocybin produced large decreases in depressed mood and anxiety…” Summary: 80% of participants maintained significant symptom relief at 6 months. Website: heffter.org (contact via site) en.wikipedia.org 1. Johns Hopkins UniversityCenter for Psychedelic and Consciousness ResearchPsilocybin for depression, anxiety, addiction, and end-of-life distressWhy it’s top-tier: The first major U.S. institution to receive regulatory approval for psychedelic research in modern times. 🔗 hopkinspsychedelic.org 2. Imperial College LondonCentre for Psychedelic ResearchPsilocybin for treatment-resistant depression, brain imaging, DMT studiesWhy it’s top-tier: Home of pioneering neuroimaging studies on psychedelics; led by Robin Carhart-Harris (now at UCSF). 🔗 imperial.ac.uk 3. Multidisciplinary Association for Psychedelic Studies (MAPS)MDMA for PTSD (now in Phase 3 trials), harm reduction, global educationWhy it’s top-tier: MAPS initiated the first FDA-approved Phase 3 trials for MDMA-assisted therapy. 🔗 maps.org4. University of California, San Francisco Psychedelic Research Program Psilocybin, DMT, ibogaine; Robin Carhart-Harris now leads U.S. armWhy it’s top-tier: Integrates neuroscience, clinical psychology, and pharmacology. 🔗 psychedelics.ucsf.edu5. NYU Langone HealthCenter for Psychedelic MedicineEnd-of-life anxiety, alcoholism, PTSD, and psilocybin studiesWhy it’s top-tier: Known for rigorous clinical trials and major collaborations. 🔗 med.nyu.edu6. University of California, Los AngelesUCLA Psychedelic Studies InitiativePsilocybin + CBT, anxiety, clinical protocolsWhy it’s top-tier: Conducting one of the few FDA-regulated psilocybin trials with integrated therapy. 🔗 uclapsi.org7. University of Wisconsin–Madison / Usona InstitutePsilocybin for major depression (FDA Phase 3 trials)Why it’s top-tier: Leading U.S.-based nonprofit with regulatory traction and major academic partnerships. 🔗 usonainstitute.org8. Massachusetts General Hospital / Harvard Medical SchoolCenter for the Neuroscience of PsychedelicsNeurobiological mechanisms of psychedelicsWhy it’s top-tier: Combines Harvard academic leadership with Mass General clinical infrastructure. 🔗 massgeneral.org9. University of New MexicoPsychedelic-Assisted Therapies & Research GroupKetamine, DMT, and MDMA research; Indigenous-informed approachesWhy it’s top-tier: Interdisciplinary and trauma-informed program with cultural awareness. 🔗 hsc.unm.edu10. Oregon Health & Science University State-licensed psilocybin therapy programs, public health, trainingWhy it’s top-tier: One of the first institutions engaging with psilocybin therapy post-legalization under Measure 109. 🔗 ohsu.edu
Hosted on Acast. See acast.com/privacy for more information.
